
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a clinical-stage precision medicine company that is transforming the drug discovery process by utilizing their Dynamo platform to target previously "intractable" protein targets. With short interest representing 24.51% of the public float, there is potential for a significant short squeeze, especially with upcoming data updates expected by the end of 2026 for their lead candidate, zovegalisib. The company's strong financial position and expanding pipeline, with key data catalysts expected into 2029, support a positive outlook for Relay Therapeutics' potential for future success in precision oncology and genetic diseases.
Bears say
Relay Therapeutics is a promising precision medicine company, but our financial analyst has a negative outlook on their stock due to several reasons. The company has a high operating expense of $91.2M in the second quarter of 2026, and they are heavily reliant on their pipeline of drug candidates, which may not be successful in clinical trials. Additionally, the analyst believes that competition for their lead drug candidate, zovegalisib, is minimal. Also, there is concern about the toxicity and limited efficacy of their drug, alpelisib, in treating a specific disease, vascular anomalies.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares